Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.
about
Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonistTumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Development of a novel DDS for site-specific PEGylated proteins.Pharmacokinetic consequences of pegylation.Optimization of protein therapies by polymer-conjugation as an effective DDS.Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.Product development issues for PEGylated proteins.Designing PEGylated therapeutic molecules: advantages in ADMET properties.Growth factor conjugation: strategies and applications.How PEGylation influences protein conformational stability.From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers.Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application.Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.Selective enhancement by tumor necrosis factor-alpha of vascular permeability of new blood vessels induced with agarose hydrogel-entrapped Meth-A fibrosarcoma cells.Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule.Preferential activity of wild-type and mutant tumor necrosis factor-alpha against tumor-derived endothelial-like cells.In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors.
P2860
Q27649040-A516F2CB-E63D-48AF-923A-F2A8CC6AFAB3Q33325343-A2CCF7F9-BD03-4D35-B489-C4A0984C9A61Q35040200-CED3DBFA-77D4-4BEF-8189-C93E2B0C2587Q36604526-86C16956-7BCA-43F1-BF33-E3D87A18D1FDQ37002679-C4C5A586-4108-439E-B5AE-BCB31C3EAC32Q37232738-C827B6C0-DEF6-4E6A-A78A-4154AD4F2D5EQ37790702-FC4C6AE8-EFE4-4B67-BBDC-6A9AFC6A7C29Q38089879-10C702D4-F80D-4704-97A0-9490F7F54637Q38204731-17AF556B-A4F4-420F-92A0-34D92777B469Q38942496-1D6B3FC4-82C2-4A11-9DBC-A8EC46EE4BD4Q39060269-340980C1-0F00-43EF-BC39-96CA43527AB0Q39211385-94ABBFEF-99D6-47FC-98B7-7797C0F6754BQ39991117-B9B86640-DCB1-4386-87AA-969D206C751DQ40069409-4C5CB33A-59B4-4EA2-8565-D613B269CCCFQ42522918-36996FB2-45C4-40B7-A2E1-ABA769D76EF6Q45876624-BFCF2B25-DF83-4E66-8FA8-ECCBF1F61930Q52538589-51C0378C-53D8-4423-9131-E1BDE3C1DC96Q54975853-69A83BF6-38FB-4F4D-B9DA-EE5285F21251
P2860
Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Molecular design of hybrid tum ...... eases its anti-tumour potency.
@ast
Molecular design of hybrid tum ...... eases its anti-tumour potency.
@en
type
label
Molecular design of hybrid tum ...... eases its anti-tumour potency.
@ast
Molecular design of hybrid tum ...... eases its anti-tumour potency.
@en
prefLabel
Molecular design of hybrid tum ...... eases its anti-tumour potency.
@ast
Molecular design of hybrid tum ...... eases its anti-tumour potency.
@en
P2093
P2860
P356
P1476
Molecular design of hybrid tum ...... eases its anti-tumour potency.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1995.186
P407
P577
1995-05-01T00:00:00Z